• XL-protein GmbH
  • Lise-Meitner-Str. 30
  • 85354 Freising/Weihenstephan
  • Germany
  • Phone: +49 (0)8161/537 30-90
  • Fax: +49 (0)8161/537 30-99
  • ed.nietorp-lx@ofni

XL-protein: Improved biopharmaceuticals with extended plasma half-life

XL-protein is a biopharmaceutical company utilizing its proprietary ‘PASylation’ technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for the life cycle management of approved biopharmaceuticals.

‘PASylation’ – the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and Ser – provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.